Current and experimental therapeutic options for cytomegalovirus disease

American Journal of Health-System Pharmacy

Volumn 53, Issue 8 SUPPL. 2, 1996, Pages

  Flaherty Jr , John F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; LOBUCAVIR; PROBENECID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DRUG IMPLANT; DRUG INDUCED DISEASE; DRUG METABOLISM; HUMAN; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETINITIS; TREATMENT OUTCOME; VIRUS INHIBITION;

EID: 19144364502     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.8_suppl_2.s4     Document Type: Conference Paper

References (25)

1. Drew WL. Cytomegalovirus infection and treatment in immunocompromised patients. In: Root RK, Sande MA, eds. Viral infections: diagnosis, treatment, and prevention. Vol. 10. New York: Churchill Livingstone; 1993:57-71.
2. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988; 108:585-94.
3. Singh N, Dummer JS, Ho M et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. 1988; 158:124-31.
4. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992; 326:213-20.
5. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophthalmology. 1994; 191:1250-61.
6. Chou S, Erice A, Jordan MC et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis. 1995; 171:576-83.
7. Drew WL, Miner RC, Busch DF et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991; 163:716-9.
8. Jacobson MA. Foscarnet therapy for AIDS-related opportunistic infections. In: Volberding P, Jacobson MA, eds. AIDS clinical review. New York: Marcel Dekker; 1992:173-87.
9. Spector SA, Busch DF, Follansbee S et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a Phase I/II Study. J Infect Dis. 1995; 171:1431-7.
10. Anderson RD, Griffy KG, Jung D et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/day dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther. 1995; 17:425-32.
11. Drew WL, Ives D, Lalezari JP et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med. 1995; 333:615-20.
12. The Oral Ganciclovir European and Australian Cooperative Study Group. Intravenous versus oral ganciclovir: European/ Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. AIDS. 1995; 9:471-7.
13. Spector SA, McKinley G, Drew WL et al. A randomized, double-blind study of the efficacy and safety of oral ganciclovir for the prevention of cytomegalovirus disease in HIV-infected persons. Paper presented at Second National Conference on Human Retroviruses and Related Infections. Washington, DC: 1995. Jan 29-Feb 1.
14. Brosgart CL, Craig C, Hillman D et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease in HIV-infected individuals with severe immunosuppression. Paper presented at 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: 1995 Sep 18.
15. Roche Laboratories, Inc.: Cytovene Complete Prescribing Information Nutley, NJ; 1995 Jan.
16. Arevalo JF, Gonzalez C, Capparelli EV et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis. 1995; 172:951-6.
17. Martin DF, Parks DJ, Mellow SD et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol. 1994; 112:1531-9.
18. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy versus monotherapy for the treatment of relapses of cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol. 1996; 114:23-33.
19. Martin JC, Hitchcock MJM. Phosphonomethylether compounds as antiviral agents. Transplant Proc. 1991; 23(Suppl. 3): 156-8.
20. Andrei G, Snoeck R, Schols D et al. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur J Clin Microbiol Infect Dis. 1991; 10:1026-33.
21. Bronson JJ, Ferrara LM, Hitchcock MJM et al. (S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): a potent antiherpesvirus agent. In: Lopez C, Mori R, Roizman B et al., eds. Immunobiology and prophylaxis of human herpes-virus infections. New York: Plenum Press; 1990:277-83.
22. Cundy KC, Petty B, Flaherty JF et al. Clinical pharmacokinetics of cidofovir (HPMPC) in HIV-infected patients. Antimicrob Agents Chemother. 1995; 39:1247-52.
23. Lalezari JP, Drew WL, Glutzer E et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995; 171:788-96.
24. Polis MA, Spooner KM, Baird BF et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995; 39:882-6.
25. Lalezari J, Holland G, Stagg R et al. A randomized, controlled study of cidofovir (CDV) for relapsing cytomegalovirus retinitis (CMV-R) in patients with AIDS. Paper presented at 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: 1995 Sep 17-20.